email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1687

Journal of Urology & Nephrology Studies

Research Article(ISSN: 2641-1687)

Efficacy and Safety of Prolonged Alfuzosin Treatment in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 7 Years of Observation

Volume 3 - Issue 1

Pavel Rasner* and Dmitriy Pushkar

  • Author Information Open or Close
    • Department of Urology, Moscow State University of Medicine and Dentistry, Moscow, Russia

    *Corresponding author: Pavel Rasner, Department of Urology, Moscow State University of Medicine and Dentistry, Moscow, Russia

Received: October 10, 2020;   Published: October 29, 2020

DOI: 10.32474/JUNS.2020.03.000154

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Introduction: Amongst all of the medications prescribed to BPH patients undergoing conservative therapy, α1-blockers were used in 80% of cases. The question of optimal treatment length is one that has been constantly asked during the last years. The current study will encompass the data we have collected of a small study group of BPH patients treated with 10 mg of Alfuzosin daily, over a period of more than 7 years.

Material and Methods: From 2009 to 2011, 41 patients with mean age 67.7 years began medical therapy taking 10 mg of Alfuzosin per day. The mean treatment length was 7.6 years as of today. 16 patients (39%) with prostates exceeding 60 cm3 were additionally prescribed 5-ARIs.

Results: Overall, a positive dynamic was found in 85.4% of patients. Not a single patient chose to discontinue treatment. A very high level of satisfaction was reported by 88% of our patients. A statistically significant (P < 0.05) decrease in IPSS scores by 8.5 ± 6.1 (47.5%) was found. Mean QoL indices decreased from 3.7 ± 1.1 to 2.3 ± 1.1 over the period of observation. Mean Qmax values increased from 9.7 ± 0.52 mL/s to 14 ± 0.60 mL/s (an increase of 44.3%).

Conclusions: This study has demonstrated a high level of safety and efficacy when using Alfuzosin to treat voiding dysfunction in patients suffering from LUTS/BPH. Our study resolves the issue surrounding a prolonged course of α1-blockers, which, due to its widespread use, remains the gold standard for medical treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Keywords: LUTS, BPH, Alfuzosin, BOO

Abstract| Introduction| Materials and Methods| Results| Discussion| Conclusions| References|